Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|April 22, 2007

Industry Veteran Joins Intranasal Therapeutics

Intranasal Therapeutics, Inc. (ITI, Montvale, NJ, www.intranasal.com), has appointed Peter F. Young as president and chief executive officer.

Intranasal Therapeutics, Inc. (ITI, Montvale, NJ, www.intranasal.com), has appointed Peter F. Young as president and chief executive officer. Young was most recently the president and CEO of AlphaVax, a North Carolina-based biotechnology company. While at AlphaVax, Young grew that company from six to 75 employees and advanced its technology from the academic bench to human clinical trials.


Related to this article

The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.